Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP19 | O94966 | 3/20 | 0.57 |
| ▸ | USP7 | Q93009 | 10/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.54 |
| ▸ | TNF | P01375 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24238980 | 0.86 | USP19 (0.78) | USP19USP7 | |
| SCHEMBL17937963 | 0.85 | HDAC6 (0.52) | USP19USP7HDAC6TNFHDAC3 | |
| SCHEMBL14744124 | 0.81 | USP7 (0.78) | USP19USP7 | |
| SCHEMBL16303296 | 0.76 | USP7 (0.73) | USP19USP7 | |
| SCHEMBL21287109 | 0.76 | USP7 (0.66) | USP19USP7 | |
| SCHEMBL24238960 | 0.74 | USP19 (0.81) | USP19 | |
| SCHEMBL23066636 | 0.73 | USP19 (1.00) | USP19 | |
| SCHEMBL21229802 | 0.73 | USP19 (1.00) | USP19 | |
| SCHEMBL29369712 | 0.73 | USP19 (1.00) | USP19 | |
| SCHEMBL14735280 | 0.73 | USP7 (0.67) | USP19USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546150-B2 | Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7 | HYBRIGENICS SA (FR) | 2017-01-17 | — | — | US | claimed |
| EP-2751092-B1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2016-07-27 | — | — | EP | claimed |
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | HYBRIGENICS SA (FR) | 2014-12-18 | — | — | US | claimed |
| EP-2751092-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Hybrigenics S.A. (FR) | 2014-07-09 | — | — | EP | claimed |
| WO-2013030218-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2013-03-07 | — | — | WO | claimed |
| EP-2565186-A1 | Selective and reversible inhibitors of ubiquitin specific protease 7 | Hybrigenics S.A. (FR) | 2013-03-06 | — | — | EP | claimed |
| US-20220125760-A1 | USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) | UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) | 2022-04-28 | — | — | US | disclosed |
| EP-3923987-A1 | USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020165315-A1 | USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-08-20 | — | — | WO | disclosed |
| US-9546150-B2 | Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7 | HYBRIGENICS SA (FR) | 2017-01-17 | — | — | US | disclosed |
| US-9546150-B2 | Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7 | HYBRIGENICS SA (FR) | 2017-01-17 | — | — | US | disclosed |
| US-9546150-B2 | Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7 | HYBRIGENICS SA (FR) | 2017-01-17 | — | — | US | disclosed |
| EP-2751092-B1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2016-07-27 | — | — | EP | disclosed |
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | HYBRIGENICS SA (FR) | 2014-12-18 | — | — | US | disclosed |
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | HYBRIGENICS SA (FR) | 2014-12-18 | — | — | US | disclosed |
| EP-2751092-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Hybrigenics S.A. (FR) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013030218-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013030218-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2013-03-07 | — | — | WO | disclosed |
| EP-2565186-A1 | Selective and reversible inhibitors of ubiquitin specific protease 7 | Hybrigenics S.A. (FR) | 2013-03-06 | — | — | EP | disclosed |
| EP-2565186-A1 | Selective and reversible inhibitors of ubiquitin specific protease 7 | Hybrigenics S.A. (FR) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | USP7, UBA7, SENP7 | USP19 20/4885USP7 1/4885HDAC6 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.